Update on Asthma–COPD Overlap (ACO): A Narrative Review

References

• Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap: clinical relevance of genomic signatures of type 2 inflammation in COPD. Am J Respir Crit Care Med. 2015;191:758–766. doi:10.1164/rccm.201408-1458OC
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Esquinas C, Miravitlles M. The asthma COPD overlap syndrome (ACOS). Opportunities and challenges. Curr Opin Pulm Med. 2015;21:74–79. doi:10.1097/MCP.0000000000000118
   PubMed Web of Science ®Google Scholar
• Orie NGM, Sluiter HJ, eds. Bronchitis. Assen, the Netherlands: Royal van Gorcum; 1962.
   Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease 2007 update. Can Respir J. 2007;14(Suppl B):5B–32B. doi:10.1155/2007/830570
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–735. doi:10.1136/thx.2008.108027
   PubMed Web of Science ®Google Scholar
• GINA-GOLD diagnosis of disease of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS). Available from: https://goldcopd.org/asthma-copd-asthma-copd-overlap-syndrome/. Accessed November 25, 2020.
   Google Scholar
• Barnes PJ. Asthma-COPD overlap. Chest. 2016;149(1):7–8. doi:10.1016/j.chest.2015.08.017
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2020 Report; 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed November 25, 2020.
   Google Scholar
• Bonten TN, Kasteleyn MJ, de Mutsert R, et al. Defining asthma-COPD overlap syndrome: a population-based study. Eur Respir J. 2017;49(5):1602008. doi:10.1183/13993003.02008-2016
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi SM, et al. Identification and definition of asthma-COPD overlap: the CanCOLD study. Respirology. 2020;25(8):836–849. doi:10.1111/resp.13780
   PubMed Web of Science ®Google Scholar
• Nuñez A, Sarasate M, Loeb E, et al. Practical guide to the identification and diagnosis of asthma-COPD overlap (ACO). COPD. 2019;16:1–7. doi:10.1080/15412555.2019.1575802
   PubMedGoogle Scholar
• Boulet LP, Boulay MÈ, Dérival JL, et al. Asthma-COPD overlap phenotypes and smoking: comparative features of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction. COPD. 2018;15(2):130–138. doi:10.1080/15412555.2017.1395834
   PubMedGoogle Scholar
• Soler-Cataluña JJ, Novella L, Soler C, et al. Clinical characteristics and risk of exacerbations associated with different diagnostic criteria of asthma-COPD overlap. Arch Bronconeumol. 2020;56(5):282–290. doi:10.1016/j.arbres.2019.08.023
   PubMed Web of Science ®Google Scholar
• Tommola M, Ilmarinen P, Tuomisto LE, et al. Differences between asthma–COPD overlap syndrome and adult-onset asthma. Eur Respir J. 2017;49(5):1602383. doi:10.1183/13993003.02383-2016
   PubMed Web of Science ®Google Scholar
• Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome (ACOS)? Towards a consensus definition from a roundtable discussion. Eur Respir J. 2016;48:664–673. doi:10.1183/13993003.00436-2016
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Alvarez-Gutierrez FJ, Calle M, et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J. 2017;49(5):1700068. doi:10.1183/13993003.00068-2017
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Kuwahira I, Hanaoka M, et al. An official JRS statement: the principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice. Respir Investig. 2021;59(1):34–52. doi:10.1016/j.resinv.2020.05.006
   PubMed Web of Science ®Google Scholar
• Mostafavi-Pour-Manshadi SM, Naderi N, Barrecheguren M, et al. Investigating fractional exhaled nitric oxide in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review. COPD. 2018;15(4):377–391. doi:10.1080/15412555.2018.1485637
   PubMedGoogle Scholar
• Japanese Respiratory Society (JRS). Definition and diagnosis of asthma-COPD overlap (ACO), the JRS guidance for the management of ACO 2018. Tokyo: Medical Review; 2017.
   Google Scholar
• Yanagisawa S, Ichinose M. Definition and diagnosis of asthma-COPD overlap (ACO). Allergol Int. 2018;67(2):172–178. doi:10.1016/j.alit.2018.01.002
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; Updated 2017. Available from: http://ginasthma.org/2017-gina-report-globalstrategy-for-asthma-management-andprevention/. Accessed November 25, 2020.
   Google Scholar
• Rhee CK, Yoon HK, Yoo KH, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD. 2014;11(2):163–170. doi:10.3109/15412555.2013.831061
   PubMedGoogle Scholar
• Krishnan JA, Nibber A, Chisholm A, et al. Prevalence and characteristics of asthma-chronic obstructive pulmonary disease overlap in routine primary care practices. Ann Am Thorac Soc. 2019;16(9):1143–1150. doi:10.1513/AnnalsATS.201809-607OC
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013;107(7):1053–1060. doi:10.1016/j.rmed.2013.03.007
   PubMed Web of Science ®Google Scholar
• de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013;8(5):e62985. doi:10.1371/journal.pone.0062985
   PubMed Web of Science ®Google Scholar
• Jo YS, Hwang YI, Yoo KH, et al. Effect of inhaled corticosteroids on exacerbation of asthma-COPD overlap according to different diagnostic criteria. J Allergy Clin Immunol Pract. 2020;8(5):1625–1633 e1626. doi:10.1016/j.jaip.2020.01.004
   PubMed Web of Science ®Google Scholar
• Milanese M, Di Marco F, Corsico AG, et al. Asthma control in elderly asthmatics. An Italian observational study. Respir Med. 2014;108(8):1091–1099. doi:10.1016/j.rmed.2014.05.016
   PubMed Web of Science ®Google Scholar
• Kiljander T, Helin T, Venho K, et al. Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15047. doi:10.1038/npjpcrm.2015.47
   PubMed Web of Science ®Google Scholar
• Hosseini M, Almasi-Hashiani A, Sepidarkish M, et al. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019;20(1):229. doi:10.1186/s12931-019-1198-4
   PubMed Web of Science ®Google Scholar
• Hiles SA, Gibson PG, McDonald VM. Disease burden of eosinophilic airway disease: comparing severe asthma, COPD and asthma-COPD overlap. Respirology. 2021;26(1):52–61. doi:10.1111/resp.13841
   PubMed Web of Science ®Google Scholar
• Nielsen M, Bårnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome–a systematic review. Int J Chron Obstruct Pulmon Dis. 2015;10:1443–1454. doi:10.2147/COPD.S85363
   PubMed Web of Science ®Google Scholar
• Brzostek D, Kokot M. Asthma-chronic obstructive pulmonary disease overlap syndrome in Poland. Findings of an epidemiological study. Postepy Dermatol Alergol. 2014;31(6):372–379. doi:10.5114/pdia.2014.47120
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Ohar JA, Croft JB, et al. Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD. 2014;11(3):256–266. doi:10.3109/15412555.2013.840571
   PubMedGoogle Scholar
• Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011;48(3):279–285. doi:10.3109/02770903.2011.555576
   PubMed Web of Science ®Google Scholar
• Fu JJ, Gibson PG, Simpson JL, et al. Longitudinal changes in clinical outcomes in older patients with asthma, COPD and asthma-COPD overlap syndrome. Respiration. 2014;87(1):63–74. doi:10.1159/000352053
   PubMed Web of Science ®Google Scholar
• Lee H, Kim SH, Kim BK, et al. Characteristics of Specialist-Diagnosed Asthma-COPD Overlap in Severe Asthma: observations from the Korean Severe Asthma Registry (KoSAR). Allergy. 2021;76(1):223–232. doi:10.1111/all.14483
   PubMed Web of Science ®Google Scholar
• Park HY, Lee SY, Kang D, et al. Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort. Respir Res. 2018;19(1):36. doi:10.1186/s12931-018-0737-8
   PubMed Web of Science ®Google Scholar
• Lange P, Çolak Y, Ingebrigtsen TS, et al. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med. 2016;4(6):454–462. doi:10.1016/S2213-2600(16)00098-9
   PubMed Web of Science ®Google Scholar
• Lee HY, Kang JY, Yoon HK, et al. Clinical characteristics of asthma combined with COPD feature. Yonsei Med J. 2014;55(4):980–986. doi:10.3349/ymj.2014.55.4.980
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Yasuo M, Hanaoka M. Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation. Int J Chron Obstruct Pulmon Dis. 2016;11:991–997. doi:10.2147/COPD.S105988
   PubMed Web of Science ®Google Scholar
• Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014;44(2):341–350. doi:10.1183/09031936.00216013
   PubMed Web of Science ®Google Scholar
• Kumbhare S, Pleasants R, Ohar JA, et al. Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. Ann Am Thorac Soc. 2016;13(6):803–810. doi:10.1513/AnnalsATS.201508-554OC
   PubMed Web of Science ®Google Scholar
• Menezes AMB, Montes de Oca M, Pérez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297–304. doi:10.1378/chest.13-0622
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Ishida M, et al. Clinical Characteristics and Outcomes of Patients with Asthma-COPD Overlap in Japanese Patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:2923–2929. doi:10.2147/COPD.S276314
   PubMed Web of Science ®Google Scholar
• Caillaud D, Chanez P, Escamilla R, et al. Asthma-COPD overlap syndrome (ACOS) vs ‘pure’ COPD: a distinct phenotype? Allergy. 2017;72(1):137–145. doi:10.1111/all.13004
   PubMed Web of Science ®Google Scholar
• Guerriero M, Caminati M, Viegi G, et al. Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population. J Asthma. 2019;56(1):27–33. doi:10.1080/02770903.2018.1424190
   PubMed Web of Science ®Google Scholar
• Jo YS, Lee J, Yoon HI, et al. Different prevalence and clinical characteristics of asthma-chronic obstructive pulmonary disease overlap syndrome according to accepted criteria. Ann Allergy Asthma Immunol. 2017;118(6):696–703.e691. doi:10.1016/j.anai.2017.04.010
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, van Zyl-smit RN, et al. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3(9):719–728. doi:10.1016/S2213-2600(15)00254-4
   PubMed Web of Science ®Google Scholar
• Hansel NN, Paré PD, Rafaels N, et al. Genome-Wide Association Study Identification of Novel Loci Associated with Airway Responsiveness in Chronic Obstructive Pulmonary Disease. Am J Respir Cell Mol Biol. 2015;53(2):226–234. doi:10.1165/rcmb.2014-0198OC
   PubMed Web of Science ®Google Scholar
• Obeidat M, Faiz A, Li X, et al. The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD. Eur Respir J. 2019;54(6):1900521. doi:10.1183/13993003.00521-2019
   PubMed Web of Science ®Google Scholar
• Tamada T, Sugiura H, Takahashi T, et al. Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. Int J Chron Obstruct Pulmon Dis. 2015;10:2169–2176. doi:10.2147/COPD.S88274
   PubMed Web of Science ®Google Scholar
• Izuhara K, Barnes PJ. Can we define asthma-COPD overlap (ACO) by biomarkers? J Allergy Clin Immunol Pract. 2019;7(1):146–147. doi:10.1016/j.jaip.2018.07.002
   PubMed Web of Science ®Google Scholar
• Gava G, Núñez A, Esquinas C, et al. Analysis of blood biomarkers in patients with Chronic Obstructive Pulmonary Disease (COPD) and with Asthma-COPD Overlap (ACO). COPD. 2020;17(3):306–310. doi:10.1080/15412555.2020.1761314
   PubMedGoogle Scholar
• de Llano LP, Cosío BG, Iglesias A, et al. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach. Int J Chron Obstruct Pulmon Dis. 2018;13:591–601. doi:10.2147/COPD.S153694
   PubMed Web of Science ®Google Scholar
• Hersh CP, Zacharia S, Prakash Arivu Chelvan R, et al.; COPDGene® Investigators. Immunoglobulin E as a biomarker for the overlap of atopic asthma and chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2020;7(1):1–12. doi:10.15326/jcopdf.7.1.2019.0138
   PubMed Web of Science ®Google Scholar
• Zeki AA, Schivo M, Chan A, et al. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy. 2011;2011:861926. doi:10.1155/2011/861926
   PubMedGoogle Scholar
• Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax. 1996;51(3):233–237. doi:10.1136/thx.51.3.233
   PubMed Web of Science ®Google Scholar
• Burrows B, Hasan FM, Barbee RA, et al. Epidemiologic observations on eosinophilia and its relation to respiratory disorders. Am Rev Respir Dis. 1980;122(5):709–719. doi:10.1164/arrd.1980.122.5.709
   PubMed Web of Science ®Google Scholar
• Platts-Mills T. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S1–S5. doi:10.1164/ajrccm.164.supplement_1.2103024
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Yamanda S, et al. Inflammatory biomarkers in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2117–2123. doi:10.2147/COPD.S113647
   PubMed Web of Science ®Google Scholar
• Toledo-Pons N, van Boven JFM, Román-Rodríguez M, et al. ACO: time to move from the description of different phenotypes to the treatable traits. PLoS One. 2019;14(1):e0210915. doi:10.1371/journal.pone.0210915
   PubMed Web of Science ®Google Scholar
• Shirai T, Hirai K, Gon Y, et al. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol Pract. 2019;7:134–145. doi:10.1016/j.jaip.2018.06.015
   PubMed Web of Science ®Google Scholar
• Ding Q, Sun S, Zhang Y, et al. Serum IL-8 and VEGFA are two promising diagnostic biomarkers of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2020;15:357–365. doi:10.2147/COPD.S233461
   PubMed Web of Science ®Google Scholar
• Ghosh N, Choudhury P, Kaushik SR, et al. Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO). Respir Res. 2020;21(1):126. doi:10.1186/s12931-020-01390-4
   PubMed Web of Science ®Google Scholar
• Asensio VJ, Tomás A, Iglesias A, et al. Eosinophilic COPD Patients Display a Distinctive Serum miRNA Profile From Asthma and Non-eosinophilic COPD. Arch Bronconeumol. 2020;56(4):234–241. doi:10.1016/j.arbres.2019.09.020
   PubMed Web of Science ®Google Scholar
• Lacedonia D, Palladino GP, Foschino-Barbaro MP, et al. Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma-COPD overlap syndrome phenotype. Int J Chron Obstruct Pulmon Dis. 2017;12:1811–1817. doi:10.2147/COPD.S130616
   PubMed Web of Science ®Google Scholar
• Kumbhare S, Strange C. Mortality in asthma-chronic obstructive pulmonary disease overlap in the United States. South Med J. 2018;111(5):293–298. doi:10.14423/SMJ.0000000000000807
   PubMed Web of Science ®Google Scholar
• Baarnes CB, Andersen ZJ, Tjønneland A, et al. Incidence and long-term outcome of severe asthma-COPD overlap compared to asthma and COPD alone: a 35-year prospective study of 57,053 middle-aged adults. Int J Chron Obstruct Pulmon Dis. 2017;12:571–579. doi:10.2147/COPD.S123167
   PubMed Web of Science ®Google Scholar
• van Boven JF, Román-Rodríguez M, Palmer JF, et al. Comorbidome, pattern, and impact of asthma-COPD overlap syndrome in real life. Chest. 2016;149(4):1011–1020. doi:10.1016/j.chest.2015.12.002
   PubMed Web of Science ®Google Scholar
• Golpe R, Suárez-Valor M, Martín-Robles I, et al. Mortality in COPD patients according to clinical phenotypes. Int J Chron Obstruct Pulmon Dis. 2018;13:1433–1439. doi:10.2147/COPD.S159834
   PubMed Web of Science ®Google Scholar
• Peltola L, Pätsi H, Harju T. COPD Comorbidities Predict High Mortality - Asthma-COPD-Overlap Has Better Prognosis. COPD. 2020;17(4):366–372. doi:10.1080/15412555.2020.1783647
   PubMedGoogle Scholar
• Sorino C, Pedone C, Scichilone N. Fifteen-year mortality of patients with asthma-COPD overlap syndrome. Eur J Intern Med. 2016;34:72–77. doi:10.1016/j.ejim.2016.06.020
   PubMed Web of Science ®Google Scholar
• Bai JW, Mao B, Yang WL, et al. Asthma-COPD overlap syndrome showed more exacerbations however lower mortality than COPD. QJM. 2017;110(7):431–436. doi:10.1093/qjmed/hcx005
   PubMed Web of Science ®Google Scholar
• Suzuki M, Makita H, Konno S, et al. Asthma-like features and clinical course of chronic obstructive pulmonary disease. An Analysis from the Hokkaido COPD Cohort Study. Am J Respir Crit Care Med. 2016;194(11):1358–1365. doi:10.1164/rccm.201602-0353OC
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Hanania NA. Management of asthma COPD overlap. Ann Allergy Asthma Immunol. 2019;123(4):335–344. doi:10.1016/j.anai.2019.07.021
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–1076. doi:10.1016/S0140-6736(03)12891-7
   PubMed Web of Science ®Google Scholar
• Busse WW, Pedersen S, Pauwels RA, et al. The inhaled steroid treatment as regular therapy in early asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2008;121(5):1167–1174. doi:10.1016/j.jaci.2008.02.029
   PubMed Web of Science ®Google Scholar
• Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306(6884):1034–1037. doi:10.1136/bmj.306.6884.1034
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15–26. doi:10.1378/chest.129.1.15
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Hardin M, Christenson SA, et al. Clinical approach to the therapy of asthma-COPD overlap. Chest. 2019;155(1):168–177. doi:10.1016/j.chest.2018.07.028
   PubMed Web of Science ®Google Scholar
• Amegadzie JE, Gorgui J, Acheampong L, et al. Comparative safety and effectiveness of inhaled bronchodilators and corticosteroids for treating asthma-COPD overlap: a systematic review and meta-analysis. J Asthma. 2019:1–16.
   Web of Science ®Google Scholar
• Stolz D, Hirsch HH, Schilter D, et al. Intensified therapy with inhaled corticosteroids and long-acting β2-agonists at the onset of upper respiratory tract infection to prevent chronic obstructive pulmonary disease exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2018;197(9):1136–1146. doi:10.1164/rccm.201709-1807OC
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741–750. doi:10.1164/rccm.200904-0492OC
   PubMed Web of Science ®Google Scholar
• Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106(3):382–389. doi:10.1016/j.rmed.2011.09.004
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;1:CD011721. doi:10.1002/14651858.CD009704.pub2
   Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, Phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021. doi:10.1016/j.rmed.2020.106021
   PubMed Web of Science ®Google Scholar
• Ishiura Y, Fujimura M, Ohkura N, et al. Effect of triple therapy in patients with asthma-COPD overlap. Int J Clin Pharmacol Ther. 2019;57(8):384–392. doi:10.5414/CP203382
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of response to roflumilast in severe chronic obstructive pulmonary disease. Pooled Analysis of Two Randomized Trials. Am J Respir Crit Care Med. 2018;198(10):1268–1278. doi:10.1164/rccm.201712-2493OC
   PubMed Web of Science ®Google Scholar
• Bateman ED, Goehring UM, Richard F, Watz H. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016;138(1):142–149. doi:10.1016/j.jaci.2015.11.035
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim JH, Park CK, et al. Effect of roflumilast on airway remodelling in a murine model of chronic asthma. Clin Exp Allergy. 2016;46(5):754–763. doi:10.1111/cea.12670
   PubMed Web of Science ®Google Scholar
• Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131(3):763–771. doi:10.1016/j.jaci.2012.12.673
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Maltby S, Gibson PG, Powell H, et al. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest. 2017;151(1):78–89. doi:10.1016/j.chest.2016.09.035
   PubMed Web of Science ®Google Scholar
• Hanania NA, Chipps BE, Griffin NM, et al. Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143(4):1629–1633.e2. doi:10.1016/j.jaci.2018.11.032
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023–1034. doi:10.1056/NEJMoa1905248
   PubMed Web of Science ®Google Scholar
• Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020;8(2):158–170. doi:10.1016/S2213-2600(19)30338-8
   PubMed Web of Science ®Google Scholar
• Krishnan JK, Voelker H, Connett JE, et al. Effect of daily azithromycin therapy and adherence on readmission risk in COPD. Eur Respir J. 2019;53(3):1801377. doi:10.1183/13993003.01377-2018
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368. doi:10.1016/S2213-2600(14)70019-0
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa1104623
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. doi:10.1016/S0140-6736(17)31281-3
   PubMed Web of Science ®Google Scholar
• Nagai A. [Guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 3rd edition]. Nihon Rinsho. 2011;69(10):1729–1734. Japanese.
   PubMedGoogle Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol. 2012;48:247–257. doi:10.1016/j.arbres.2012.04.001
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48:331–337. doi:10.1016/j.arbres.2011.12.009
   PubMed Web of Science ®Google Scholar
• Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines Biomed of the Czech Pneumological and Phthisiological society: a novel phenotypic approach to COPD with patient oriented care. Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:189–201. doi:10.5507/bp.2013.039
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Harju T, Kilpeläinen M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the Finish guidelines. Basic Clin Pharmacol Toxicol. 2015;116:291–307. doi:10.1111/bcpt.12366
   PubMed Web of Science ®Google Scholar
• Mahboud BH, Vats MG, Al Zaabi A, et al. Joint Statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017. Int J Chron Obstruct Pulmon Dis. 2017;12:2869–2890. doi:10.2147/COPD.S136245
   PubMed Web of Science ®Google Scholar
• Plaza V, Alvarez F, Calle M, et al. Consensus on the asthma-COPD overlap syndrome (ACOS) between the Spanish COPD guidelines (GesEPOC) and the Spanish guidelines on the management of asthma (GEMA). Arch Bronconeumol. 2017;53:443–449. doi:10.1016/j.arbres.2017.04.002
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Diagnosis of asthma-COPD overlap: the five commandments. Eur Respir J. 2017;49:1700506. doi:10.1183/13993003.00506-2017
   PubMed Web of Science ®Google Scholar
• Araújo D, Padrão E, Morais-Almeida M, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome - Literature review and contributions towards a Portuguese consensus. Rev Port Pneumol. 2017;23(2):90–99. doi:10.1016/j.rppnen.2016.11.005
   PubMed Web of Science ®Google Scholar
• Global initiative for asthma (GINA) 2020 report. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf. Accessed March 23, 2021.
   Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3(4):210–232. doi:10.1080/24745332.2019.1668652
   Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Update of the Spanish guideline for COPD (GesEPOC) 2021: pharmacological treatment of stable COPD. Arch Bronconeumol. 2021:S0300-2896(21)00103-4. doi:10.1016/j.arbres.2021.03.005
   Web of Science ®Google Scholar
• Montes de Oca M, López Varela MV, Acuña A, et al. Incorporating new evidence on inhaled medications in COPD. The Latin American Chest Association (ALAT) 2019. Arch Bronconeumol. 2020;56(2):106–113. doi:10.1016/j.arbres.2019.09.023
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in chronic obstructive pulmonary disease: a European Respiratory Society Guideline. Eur Respir J. 2020;35:2000351. doi:10.1183/13993003.00351-2020
   Web of Science ®Google Scholar
• Miravitlles M. Asthma-COPD overlap (ACO) PRO-CON debate. ACO: call me by my name. COPD. 2020;17(5):471–473. doi:10.1080/15412555.2020.1817883
   PubMedGoogle Scholar
• Papi A. Asthma COPD overlap PRO-CON debate. ACO: the Mistaken Term. COPD. 2020;17(5):474–476. doi:10.1080/15412555.2020.1817882
   PubMedGoogle Scholar
• Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax. 2008;63(9):761–767. doi:10.1136/thx.2007.089193
   PubMed Web of Science ®Google Scholar
• Morgan BW, Grigsby MR, Siddharthan T, et al. Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. J Allergy Clin Immunol. 2019;143(4):1598–1606. doi:10.1016/j.jaci.2018.06.052
   PubMed Web of Science ®Google Scholar